EA
ADVM

Emerald Advisers’s Adverum Biotechnologies ADVM Stock Holding History

Emerald Advisers’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-14,107
Closed -$5.12M – 319
2015
Q1 		$5.12M Buy
+14,107
New +$5.96M 0.26% 125

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Emerald Advisers's ADVM Position: Q2 2015 in Review

Emerald Advisers sold out of Adverum Biotechnologies (ADVM) in Q2 2015, closing a stake of 14,107 shares — an estimated $5.12M sold.

Emerald Advisers first reported a position in ADVM in Q1 2015 and held it in 1 quarter. The position peaked at $5.12M in Q1 2015. 96 funds tracked by Wall St. Rank hold ADVM as of Q2 2015.

  • Emerald Advisers reported no remaining Adverum Biotechnologies position as of Q2 2015 after selling out during the quarter.
  • Emerald Advisers sold 14,107 Adverum Biotechnologies shares in Q2 2015, an estimated $5.12M.
  • Emerald Advisers first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 1 quarter.
  • Emerald Advisers's Adverum Biotechnologies position peaked at $5.12M in Q1 2015.
  • 96 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2015.

Based on Emerald Advisers's 13F filing for Q2 2015, filed 28 Jul 2015.